Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial
Neurooncol Adv. 2022 Jan 27;4(1):vdac011.
doi: 10.1093/noajnl/vdac011.
eCollection 2022 Jan-Dec.
1 Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
2 Department of Public Health Sciences, Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.
3 Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
4 Department of Radiation Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
5 Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
6 Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
7 Department of Experimental Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
8 Department of Medical oncology, IRCCS Istituto Scienze Neurologiche - Bologna, Italy.
9 Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
10 Genesis Cancer Care, Newcastle, NSW, Australia.
11 Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Japan.
12 QOL Consulting, West Vancouver, British Columbia, Canada.
13 Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
14 Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
15 Division of Neurology, Heidelberg University Medical Center, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.